tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.
Also called NCT04248868
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 109 participants
- Registry
-
NCT04248868
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04248868. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-23 (actual); primary completion 2022-06-22 (actual). Results posted on 2023-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
- Acronym
- RESCUE
- Condition
- Pulmonary Embolism
- Intervention (Device)
- The Bashir™ Endovascular Catheter
- Intervention (Drug)
- r-tPA
- Lead sponsor
- Thrombolex, Inc.
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct04248868- Content hash
ebc6cd0982fa2c7b9818c13b9458a0c6ce0a7212d5655519034d5e1bb3527dd5